However, some NSCLC patients show resistance to osimertinib treatment, and the previous study showed that one of the mechanisms of the resistance was the activation of the bypass growth signaling pathway by AXL (Taniguchi et al. Here, AXL is linked to non-small cell lung carcinoma.